{"id":73462,"date":"2026-04-17T16:06:01","date_gmt":"2026-04-17T10:36:01","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=73462"},"modified":"2026-04-17T16:06:02","modified_gmt":"2026-04-17T10:36:02","slug":"neuland-laboratories-q4-results-2026-preview","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/neuland-laboratories-q4-results-2026-preview\/","title":{"rendered":"Neuland Laboratories Q4 Results 2026: Date, Revenue, PAT &amp; Analyst Outlook"},"content":{"rendered":"<p>Neuland Laboratories (NSE: NEULANDLAB) is preparing to announce its Q4 FY26 financial results for the quarter ending March 31, 2026. With the stock trading at Rs 11,200 and a 52-week range of Rs 9,800\u2013Rs 18,500, the Q4 FY26 results will be a pivotal event for investors tracking the Pharma sector. This article covers the confirmed results date, Q4 FY26 analyst earnings estimates, five key performance drivers, five risks to monitor, and analyst ratings with price targets ahead of the results announcement.<\/p><p>Q4 FY26 (January to March 2026) is the final quarter of the financial year, carrying special importance as it determines the full-year FY26 performance baseline, sets FY27 estimate benchmarks, and typically triggers final dividend announcements. For Pharma companies, Q4 is historically a seasonally important quarter influenced by year-end government spending, project completions, and management guidance for the year ahead.<\/p><p>Investors should monitor three data points when results are announced: the revenue and PAT numbers relative to the estimates provided in this article, any formal FY27 guidance, and the dividend recommendation from the board. For real-time analysis and SEBI-registered expert views on Neuland Laboratories, visit&nbsp;<\/p><div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/neuland-laboratories-q4-results-2026-preview\/#Neuland_Laboratories_Q4_Results_2026_Date\" title=\"Neuland Laboratories Q4 Results 2026 Date\">Neuland Laboratories Q4 Results 2026 Date<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/neuland-laboratories-q4-results-2026-preview\/#Why_This_Quarter_Matters\" title=\"Why This Quarter Matters\">Why This Quarter Matters<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/neuland-laboratories-q4-results-2026-preview\/#Neuland_Laboratories_Q4_FY26_Earnings_Estimates\" title=\"Neuland Laboratories Q4 FY26 Earnings Estimates\">Neuland Laboratories Q4 FY26 Earnings Estimates<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/neuland-laboratories-q4-results-2026-preview\/#5_Key_Factors_That_Will_Drive_Neuland_Laboratories_Q4_FY26_Performance\" title=\"5 Key Factors That Will Drive Neuland Laboratories Q4 FY26 Performance\">5 Key Factors That Will Drive Neuland Laboratories Q4 FY26 Performance<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/neuland-laboratories-q4-results-2026-preview\/#Pharma_Sector_Demand_in_Q4_FY26\" title=\"Pharma Sector Demand in Q4 FY26\">Pharma Sector Demand in Q4 FY26<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/neuland-laboratories-q4-results-2026-preview\/#Operating_Leverage_and_Margin_Expansion\" title=\"Operating Leverage and Margin Expansion\">Operating Leverage and Margin Expansion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/neuland-laboratories-q4-results-2026-preview\/#Management_Execution_on_FY26_Annual_Targets\" title=\"Management Execution on FY26 Annual Targets\">Management Execution on FY26 Annual Targets<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/neuland-laboratories-q4-results-2026-preview\/#Capital_Allocation_and_Dividend_Policy\" title=\"Capital Allocation and Dividend Policy\">Capital Allocation and Dividend Policy<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/neuland-laboratories-q4-results-2026-preview\/#FY27_Guidance_as_Primary_Re-Rating_Catalyst\" title=\"FY27 Guidance as Primary Re-Rating Catalyst\">FY27 Guidance as Primary Re-Rating Catalyst<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/neuland-laboratories-q4-results-2026-preview\/#5_Risks_to_Watch_in_Neuland_Laboratories_Q4_FY26\" title=\"5 Risks to Watch in Neuland Laboratories Q4 FY26\">5 Risks to Watch in Neuland Laboratories Q4 FY26<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/neuland-laboratories-q4-results-2026-preview\/#Revenue_Miss_Risk_vs_Q4_Estimates\" title=\"Revenue Miss Risk vs Q4 Estimates\">Revenue Miss Risk vs Q4 Estimates<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/neuland-laboratories-q4-results-2026-preview\/#Margin_Compression_from_Cost_or_Pricing_Pressure\" title=\"Margin Compression from Cost or Pricing Pressure\">Margin Compression from Cost or Pricing Pressure<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/neuland-laboratories-q4-results-2026-preview\/#FII_Selling_and_Macro_Headwinds\" title=\"FII Selling and Macro Headwinds\">FII Selling and Macro Headwinds<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/neuland-laboratories-q4-results-2026-preview\/#FY27_Guidance_Disappointment\" title=\"FY27 Guidance Disappointment\">FY27 Guidance Disappointment<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/neuland-laboratories-q4-results-2026-preview\/#Sector-Specific_Regulatory_and_Policy_Risk\" title=\"Sector-Specific Regulatory and Policy Risk\">Sector-Specific Regulatory and Policy Risk<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/neuland-laboratories-q4-results-2026-preview\/#Neuland_Laboratories_Share_Price_and_Analyst_Ratings\" title=\"Neuland Laboratories Share Price and Analyst Ratings\">Neuland Laboratories Share Price and Analyst Ratings<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/neuland-laboratories-q4-results-2026-preview\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/neuland-laboratories-q4-results-2026-preview\/#Frequently_Asked_Questions\" title=\"Frequently Asked Questions\">Frequently Asked Questions<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/neuland-laboratories-q4-results-2026-preview\/#What_is_the_Neuland_Laboratories_Q4_results_2026_date\" title=\"What is the Neuland Laboratories Q4 results 2026 date?\">What is the Neuland Laboratories Q4 results 2026 date?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/neuland-laboratories-q4-results-2026-preview\/#What_is_the_Neuland_Laboratories_Q4_FY26_PAT_estimate\" title=\"What is the Neuland Laboratories Q4 FY26 PAT estimate?\">What is the Neuland Laboratories Q4 FY26 PAT estimate?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/univest.in\/blogs-2\/neuland-laboratories-q4-results-2026-preview\/#What_is_Neuland_Laboratoriess_share_price_ahead_of_Q4_results\" title=\"What is Neuland Laboratories&#8217;s share price ahead of Q4 results?\">What is Neuland Laboratories&#8217;s share price ahead of Q4 results?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/univest.in\/blogs-2\/neuland-laboratories-q4-results-2026-preview\/#Will_Neuland_Laboratories_declare_a_dividend_in_Q4_2026\" title=\"Will Neuland Laboratories declare a dividend in Q4 2026?\">Will Neuland Laboratories declare a dividend in Q4 2026?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-23\" href=\"https:\/\/univest.in\/blogs-2\/neuland-laboratories-q4-results-2026-preview\/#Which_analysts_have_a_Buy_rating_on_Neuland_Laboratories\" title=\"Which analysts have a Buy rating on Neuland Laboratories?\">Which analysts have a Buy rating on Neuland Laboratories?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-24\" href=\"https:\/\/univest.in\/blogs-2\/neuland-laboratories-q4-results-2026-preview\/#What_were_Neuland_Laboratories_Q3_FY26_results\" title=\"What were Neuland Laboratories Q3 FY26 results?\">What were Neuland Laboratories Q3 FY26 results?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-25\" href=\"https:\/\/univest.in\/blogs-2\/neuland-laboratories-q4-results-2026-preview\/#When_do_Infosys_and_TCS_announce_Q4_results_2026\" title=\"When do Infosys and TCS announce Q4 results 2026?\">When do Infosys and TCS announce Q4 results 2026?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-26\" href=\"https:\/\/univest.in\/blogs-2\/neuland-laboratories-q4-results-2026-preview\/#Is_Neuland_Laboratories_a_good_investment_ahead_of_Q4_results\" title=\"Is Neuland Laboratories a good investment ahead of Q4 results?\">Is Neuland Laboratories a good investment ahead of Q4 results?<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-27\" href=\"https:\/\/univest.in\/blogs-2\/neuland-laboratories-q4-results-2026-preview\/#Recent_Article\" title=\"Recent Article\">Recent Article<\/a><\/li><\/ul><\/nav><\/div>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Neuland_Laboratories_Q4_Results_2026_Date\"><\/span><strong>Neuland Laboratories Q4 Results 2026 Date<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>Get free investment predictions and live Q4 result alerts on <a href=\"https:\/\/univest.in\/user\/log-in\">Univest<\/a>.<\/p><p>Neuland Laboratories has scheduled its Q4 FY26 results for May 12, 2026. The board of directors will convene to approve audited financial statements for the quarter and full year ended March 31, 2026, and consider a final dividend recommendation.<\/p><figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Company<\/strong><\/td><td><strong>Q4 FY26 Results Date<\/strong><\/td><td><strong>Article Link<\/strong><\/td><\/tr><tr><td>TCS<\/td><td>April 9, 2026<\/td><td><a href=\"https:\/\/univest.in\/blogs\/tcs-q4-results-2026-date-preview\">Read TCS Q4 Preview<\/a><\/td><\/tr><tr><td>Infosys<\/td><td>April 23, 2026<\/td><td><a href=\"https:\/\/univest.in\/blogs\/infosys-q4-results-2026-date-preview\">Read Infosys Q4 Preview<\/a><\/td><\/tr><tr><td>Neuland Laboratories<\/td><td>May 12, 2026<\/td><td>This article<\/td><\/tr><\/tbody><\/table><\/figure><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Why_This_Quarter_Matters\"><\/span><strong>Why This Quarter Matters<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>Q4 FY26 is the final quarter of the financial year \u2014 it determines full-year FY26 performance, establishes FY27 estimate baselines, and triggers final dividend announcements. For Neuland Laboratories, Q4 matters because the stock has delivered a -32% return over the past year, making the Q4 growth trajectory and management guidance crucial for sentiment recovery.<\/p><p>Institutional investors typically rebalance portfolios at the end of March, and Q4 results provide the data clarity needed for positioning into the new financial year. Analyst targets \u2014 ranging from Rs 14,200 to Rs 14,500 \u2014 will be updated post-results based on actual Q4 performance and FY27 guidance.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Neuland_Laboratories_Q4_FY26_Earnings_Estimates\"><\/span><strong>Neuland Laboratories Q4 FY26 Earnings Estimates<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><figure class=\"wp-block-image size-large\"><img fetchpriority=\"high\" decoding=\"async\" width=\"1024\" height=\"536\" src=\"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17160439\/neuland-laboratories-q4-fy26-analyst-estimates-1024x536.jpg\" alt=\"Neuland Laboratories Q4 FY26 Earnings Estimates\" class=\"wp-image-73478\" srcset=\"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17160439\/neuland-laboratories-q4-fy26-analyst-estimates-1024x536.jpg 1024w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17160439\/neuland-laboratories-q4-fy26-analyst-estimates-300x157.jpg 300w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17160439\/neuland-laboratories-q4-fy26-analyst-estimates-768x402.jpg 768w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17160439\/neuland-laboratories-q4-fy26-analyst-estimates-900x471.jpg 900w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17160439\/neuland-laboratories-q4-fy26-analyst-estimates-600x314.jpg 600w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17160439\/neuland-laboratories-q4-fy26-analyst-estimates-150x79.jpg 150w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17160439\/neuland-laboratories-q4-fy26-analyst-estimates.jpg 1200w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure><p>Access premium SEBI-registered research on <a href=\"https:\/\/univest.in\/user\/log-in\">Univest<\/a>.<\/p><p>Analysts from MOFSL, YES Securities, JM Financial, and ICICI Direct have published Q4 FY26 preview estimates for Neuland Laboratories. Consensus revenue stands at Rs 510\u2013540 Cr, compared to Rs 440 Cr in Q3 FY26. PAT is estimated at Rs 72\u201390 Cr, with margin of EBITDA 20\u201323%.<\/p><figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Metric<\/strong><\/td><td><strong>Q3 FY26 Actual<\/strong><\/td><td><strong>Q4 FY26 Estimate<\/strong><\/td><td><strong>Key Driver<\/strong><\/td><\/tr><tr><td>Revenue<\/td><td>Rs 440 Cr<\/td><td>Rs 510\u2013540 Cr<\/td><td>Seasonal demand + YoY growth<\/td><\/tr><tr><td>PAT<\/td><td>Rs 41 Cr<\/td><td>Rs 72\u201390 Cr<\/td><td>Operating leverage improvement<\/td><\/tr><tr><td>Margin<\/td><td>EBITDA 21.6%<\/td><td>EBITDA 20\u201323%<\/td><td>Cost control + pricing<\/td><\/tr><tr><td>Growth (YoY)<\/td><td>\u2014<\/td><td>15\u201322% YoY<\/td><td>Volume\/price mix<\/td><\/tr><tr><td>Dividend (Expected)<\/td><td>\u2014<\/td><td>Rs 20\u201330 per share<\/td><td>Board discretion<\/td><\/tr><\/tbody><\/table><\/figure><p>Beyond the headline numbers, investors should watch FY27 revenue and margin guidance and the dividend declaration, as these will carry more weight for the stock&#8217;s re-rating than Q4 numbers alone.<\/p><p>Screen Neuland Laboratories fundamentals on the <a href=\"https:\/\/univest.in\/screeners\">Univest Screener<\/a>.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"5_Key_Factors_That_Will_Drive_Neuland_Laboratories_Q4_FY26_Performance\"><\/span><strong>5 Key Factors That Will Drive Neuland Laboratories Q4 FY26 Performance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Pharma_Sector_Demand_in_Q4_FY26\"><\/span><strong>Pharma Sector Demand in Q4 FY26<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Neuland Laboratories operates in the Pharma sector. Q4 FY26 has seen demand supported by year-end government spending, improving consumer activity, and global trade recovery. The company&#8217;s established market position enables it to capture incremental demand. Analysts project 15\u201322% YoY revenue growth for Q4 FY26, driven by volume improvement and pricing stability.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Operating_Leverage_and_Margin_Expansion\"><\/span><strong>Operating Leverage and Margin Expansion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Higher volumes in Q4 FY26 enable improved fixed cost absorption at Neuland Laboratories&#8217;s operations. The EBITDA margin is expected to expand toward EBITDA 20\u201323%, up from EBITDA 21.6% in Q3 FY26. This improvement is driven by a combination of better product mix, cost efficiencies, and operational scale benefits. PAT growth from Rs 41 Cr in Q3 to Rs 72\u201390 Cr in Q4 reflects this operating leverage.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Management_Execution_on_FY26_Annual_Targets\"><\/span><strong>Management Execution on FY26 Annual Targets<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Q4 FY26 is the final quarter of the financial year, and Neuland Laboratories&#8217;s management will be working to deliver on the full-year FY26 commitments made at the start of the year. Strong Q4 execution would validate management credibility and set a positive base for FY27 guidance. Any formal FY27 outlook will be closely tracked by analysts and institutional investors.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Capital_Allocation_and_Dividend_Policy\"><\/span><strong>Capital Allocation and Dividend Policy<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>The board of Neuland Laboratories is expected to consider Rs 20\u201330 per share as a final dividend at the Q4 FY26 results board meeting. The quantum of the dividend signals management&#8217;s confidence in the company&#8217;s free cash flow generation and capital allocation discipline. A higher-than-expected dividend would be a positive catalyst for investor sentiment.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"FY27_Guidance_as_Primary_Re-Rating_Catalyst\"><\/span><strong>FY27 Guidance as Primary Re-Rating Catalyst<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Beyond Q4 FY26 results, the management&#8217;s FY27 guidance \u2014 for revenue growth, margin outlook, and capital expenditure \u2014 will be the most market-moving element of the results announcement. Analyst price targets for Neuland Laboratories range from Rs 14,200 to Rs 14,500, and these will be revised post-results based on the guidance delivered.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"5_Risks_to_Watch_in_Neuland_Laboratories_Q4_FY26\"><\/span><strong>5 Risks to Watch in Neuland Laboratories Q4 FY26<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Revenue_Miss_Risk_vs_Q4_Estimates\"><\/span><strong>Revenue Miss Risk vs Q4 Estimates<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>If Neuland Laboratories&#8217;s Q4 FY26 revenue falls below the Rs 510\u2013540 Cr estimate \u2014 due to execution delays, demand softness, or order cancellations \u2014 the stock could correct sharply. Revenue delivery versus estimates is the first watchpoint on results day. Even a small miss can trigger outsized selling in the current high-uncertainty macro environment.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Margin_Compression_from_Cost_or_Pricing_Pressure\"><\/span><strong>Margin Compression from Cost or Pricing Pressure<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Input cost increases, competitive pricing pressure, or adverse product mix in Q4 FY26 could compress Neuland Laboratories&#8217;s margins below the EBITDA 20\u201323% estimate. A margin miss combined with revenue shortfall would be the worst-case outcome for near-term stock performance, potentially pushing the stock below the 52-week low of Rs 9,800.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"FII_Selling_and_Macro_Headwinds\"><\/span><strong>FII Selling and Macro Headwinds<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>The 26% US reciprocal tariff on Indian goods announced in April 2026 has triggered FII selling in Indian equities, creating a macro overhang. For Neuland Laboratories, indirect impacts include valuation multiple compression and reduced institutional demand for mid-cap and small-cap stocks regardless of company-specific fundamentals.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"FY27_Guidance_Disappointment\"><\/span><strong>FY27 Guidance Disappointment<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>In the current market environment, forward guidance carries significantly more weight than the reported quarter. If management&#8217;s FY27 revenue or margin guidance at the Q4 results call falls below Street expectations, Neuland Laboratories&#8217;s stock could underperform even if Q4 numbers are in line with estimates.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Sector-Specific_Regulatory_and_Policy_Risk\"><\/span><strong>Sector-Specific Regulatory and Policy Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>The Pharma sector faces an evolving regulatory landscape. Policy changes \u2014 including environmental regulations, tax changes, or sector-specific compliance requirements \u2014 that increase costs or alter competitive dynamics could affect Neuland Laboratories&#8217;s profitability in ways not currently modelled in analyst consensus estimates.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Neuland_Laboratories_Share_Price_and_Analyst_Ratings\"><\/span><strong>Neuland Laboratories Share Price and Analyst Ratings<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"536\" src=\"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17160521\/neuland-laboratories-q4-fy26-share-price-analyst-ratings-1024x536.jpg\" alt=\"Neuland Laboratories Share Price and Analyst Ratings\" class=\"wp-image-73481\" srcset=\"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17160521\/neuland-laboratories-q4-fy26-share-price-analyst-ratings-1024x536.jpg 1024w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17160521\/neuland-laboratories-q4-fy26-share-price-analyst-ratings-300x157.jpg 300w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17160521\/neuland-laboratories-q4-fy26-share-price-analyst-ratings-768x402.jpg 768w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17160521\/neuland-laboratories-q4-fy26-share-price-analyst-ratings-900x471.jpg 900w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17160521\/neuland-laboratories-q4-fy26-share-price-analyst-ratings-600x314.jpg 600w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17160521\/neuland-laboratories-q4-fy26-share-price-analyst-ratings-150x79.jpg 150w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17160521\/neuland-laboratories-q4-fy26-share-price-analyst-ratings.jpg 1200w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure><p>Neuland Laboratories is trading at Rs 11,200 as of early April 2026, against a 52-week high of Rs 18,500 and 52-week low of Rs 9,800. The 1-year return of -32% reflects sector headwinds. Market capitalisation stands at Rs 12,300 Cr.<\/p><figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Brokerage<\/strong><\/td><td><strong>Rating<\/strong><\/td><td><strong>Target Price<\/strong><\/td><td><strong>Investment Thesis<\/strong><\/td><\/tr><tr><td>MOFSL<\/td><td>Buy<\/td><td>Rs 14,500<\/td><td>Complex API leadership expanding<\/td><\/tr><tr><td>YES Securities<\/td><td>Buy<\/td><td>Rs 14,000<\/td><td>GDS segment high growth<\/td><\/tr><tr><td>JM Financial<\/td><td>Outperform<\/td><td>Rs 13,500<\/td><td>Innovation API pipeline robust<\/td><\/tr><tr><td>ICICI Direct<\/td><td>Buy<\/td><td>Rs 14,200<\/td><td>Export partners upgrading contracts<\/td><\/tr><\/tbody><\/table><\/figure><p>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Neuland Laboratories&#8217;s live price and receive SEBI-backed research alerts.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>Neuland Laboratories enters Q4 FY26 with Pharma sector tailwinds and management focused on delivering full-year FY26 targets. Revenue of Rs 510\u2013540 Cr and PAT of Rs 72\u201390 Cr represent the analyst consensus expectation. The predominantly bullish analyst view \u2014 with targets ranging from Rs 14,200 to Rs 14,500 \u2014 suggests meaningful upside potential from the current price of Rs 11,200, contingent on Q4 results delivering to estimates and FY27 guidance being constructive. Investors should monitor Q4 revenue versus estimate, margin versus EBITDA 20\u201323% band, and FY27 guidance when results are announced on May 12, 2026.<\/p><p>This article is for informational and educational purposes only. Consult a SEBI-registered financial advisor before making investment decisions.<\/p><p>For more Q4 FY26 results previews, visit <a href=\"https:\/\/univest.in\/blogs\">Univest Blogs<\/a>.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions\"><\/span><strong>Frequently Asked Questions<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_is_the_Neuland_Laboratories_Q4_results_2026_date\"><\/span><strong>What is the Neuland Laboratories Q4 results 2026 date?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>The Neuland Laboratories Q4 FY26 results date is May 12, 2026. The board will meet to approve audited Q4 FY26 financials and consider a dividend recommendation.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_is_the_Neuland_Laboratories_Q4_FY26_PAT_estimate\"><\/span><strong>What is the Neuland Laboratories Q4 FY26 PAT estimate?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Analysts estimate Neuland Laboratories Q4 FY26 PAT at Rs 72\u201390 Cr, based on revenue of Rs 510\u2013540 Cr and margin of EBITDA 20\u201323%.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_is_Neuland_Laboratoriess_share_price_ahead_of_Q4_results\"><\/span><strong>What is Neuland Laboratories&#8217;s share price ahead of Q4 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Neuland Laboratories is trading at Rs 11,200. The 52-week high is Rs 18,500 and low is Rs 9,800. 1-year return is -32% and market cap is Rs 12,300 Cr.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Will_Neuland_Laboratories_declare_a_dividend_in_Q4_2026\"><\/span><strong>Will Neuland Laboratories declare a dividend in Q4 2026?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Neuland Laboratories is expected to consider Rs 20\u201330 per share as a final dividend. The actual declaration will depend on Q4 FY26 profitability and the board&#8217;s capital allocation policy.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Which_analysts_have_a_Buy_rating_on_Neuland_Laboratories\"><\/span><strong>Which analysts have a Buy rating on Neuland Laboratories?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>MOFSL (Target: Rs 14,500), YES Securities (Target: Rs 14,000), JM Financial (Target: Rs 13,500), ICICI Direct (Target: Rs 14,200) have positive ratings on Neuland Laboratories heading into Q4 FY26 results.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_were_Neuland_Laboratories_Q3_FY26_results\"><\/span><strong>What were Neuland Laboratories Q3 FY26 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Neuland Laboratories reported revenue of Rs 440 Cr and PAT of Rs 41 Cr in Q3 FY26, with margin at EBITDA 21.6%. These form the base for Q4 FY26 consensus estimates.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"When_do_Infosys_and_TCS_announce_Q4_results_2026\"><\/span><strong>When do Infosys and TCS announce Q4 results 2026?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>TCS announced Q4 FY26 results on April 9, 2026. Read the <a href=\"https:\/\/univest.in\/blogs\/tcs-q4-results-2026-date-preview\">TCS Q4 Results 2026 preview<\/a>. Infosys announced Q4 FY26 results on April 23, 2026. Read the <a href=\"https:\/\/univest.in\/blogs\/infosys-q4-results-2026-date-preview\">Infosys Q4 Results 2026 preview<\/a>.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Is_Neuland_Laboratories_a_good_investment_ahead_of_Q4_results\"><\/span><strong>Is Neuland Laboratories a good investment ahead of Q4 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>This depends on your risk appetite and portfolio context. Use the&nbsp; to assess Neuland Laboratories fundamentals, and consult a SEBI-registered financial advisor before making investment decisions.<\/p><p>Disclaimer: Investment in the share market is subject to risk. This article is for informational and educational purposes only and does not constitute investment advice. All financial data and analyst estimates are sourced from publicly available information including NSE\/BSE filings and company investor relations pages. Verify all numbers before investing. Consult a SEBI-registered advisor before making investment decisions.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Recent_Article\"><\/span><strong>Recent Article<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p><a href=\"https:\/\/univest.in\/blogs\/motisons-jewellers-q4-results-2026\">Motisons Jewellers Q4 Results 2026: Date, Revenue, PAT &amp; Analyst Outlook<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/motilal-oswal-financial-services-q4-results-2026\">Motilal Oswal Financial Services Q4 Results 2026: Date, Revenue, PAT &amp; Analyst Outlook<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/moschip-technologies-q4-results-2026\">Moschip Technologies Q4 Results 2026: Date, Revenue, PAT &amp; Analyst Outlook<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/morepen-laboratories-q4-results-2026\">Morepen Laboratories Q4 Results 2026: Date, Revenue, PAT &amp; Analyst Outlook<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/morarjee-textiles-q4-results-2026\">Morarjee Textiles Q4 Results 2026: Date, Revenue, PAT &amp; Analyst Outlook<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Neuland Laboratories (NSE: NEULANDLAB) is preparing to announce its Q4 FY26 financial results for the quarter ending March 31, 2026. With the stock trading at Rs 11,200 and a 52-week range of Rs 9,800\u2013Rs 18,500, the Q4 FY26 results will be a pivotal event for investors tracking the Pharma sector. This article covers the confirmed<\/p>\n","protected":false},"author":26,"featured_media":73473,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[],"class_list":["post-73462","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"metadata":{"_edit_lock":["1776422262:26"],"_last_editor_used_jetpack":["block-editor"],"rank_math_internal_links_processed":["1"],"amazonS3_cache":["a:8:{s:98:\"\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/04\/neuland-laboratories-q4-fy26-analyst-estimates.jpg\";a:2:{s:2:\"id\";i:73478;s:11:\"source_type\";s:13:\"media-library\";}s:107:\"\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/04\/neuland-laboratories-q4-fy26-analyst-estimates-1024x536.jpg\";a:2:{s:2:\"id\";i:73478;s:11:\"source_type\";s:13:\"media-library\";}s:130:\"\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17160439\/neuland-laboratories-q4-fy26-analyst-estimates.jpg\";a:2:{s:2:\"id\";i:73478;s:11:\"source_type\";s:13:\"media-library\";}s:139:\"\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17160439\/neuland-laboratories-q4-fy26-analyst-estimates-1024x536.jpg\";a:2:{s:2:\"id\";i:73478;s:11:\"source_type\";s:13:\"media-library\";}s:108:\"\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/04\/neuland-laboratories-q4-fy26-share-price-analyst-ratings.jpg\";a:2:{s:2:\"id\";i:73481;s:11:\"source_type\";s:13:\"media-library\";}s:117:\"\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/04\/neuland-laboratories-q4-fy26-share-price-analyst-ratings-1024x536.jpg\";a:2:{s:2:\"id\";i:73481;s:11:\"source_type\";s:13:\"media-library\";}s:140:\"\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17160521\/neuland-laboratories-q4-fy26-share-price-analyst-ratings.jpg\";a:2:{s:2:\"id\";i:73481;s:11:\"source_type\";s:13:\"media-library\";}s:149:\"\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17160521\/neuland-laboratories-q4-fy26-share-price-analyst-ratings-1024x536.jpg\";a:2:{s:2:\"id\";i:73481;s:11:\"source_type\";s:13:\"media-library\";}}"],"rank_math_primary_category":["842"],"rank_math_seo_score":["87"],"rank_math_focus_keyword":["Neuland Laboratories"],"rank_math_title":["Neuland Laboratories Q4 Results 2026: Date, Revenue &amp; Analyst Outlook"],"rank_math_description":[" Neuland Laboratories Q4 results on May 12, 2026. Revenue estimate Rs 510\u2013540 Cr, PAT Rs 72\u201390 Cr. Complex API leadership and GDS segment drive high-growth Q4 FY26.\n"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"],"_thumbnail_id":["73473"],"_edit_last":["26"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["8425"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17160359\/neuland-laboratories-q4-fy26-results-date-preview.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/73462","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/26"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=73462"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/73462\/revisions"}],"predecessor-version":[{"id":73483,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/73462\/revisions\/73483"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/73473"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=73462"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=73462"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=73462"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}